title: Combination therapy in a transgenic model of Alzheimer's disease.
abstract: The pathological accumulation of the β-amyloid protein (Aβ) has been closely associated with synaptic loss and neurotoxicity contributing to cognitive dysfunction in Alzheimer's disease (AD). Oligomers of Aβ42 appear to be the most neurotoxic form. Two of the most promising attempts to reduce Aβ accumulation have been with scyllo-inositol, an inositol steroisomer, that stabilizes Aβ42 peptide and prevents it from progressing to oligomers and fibrils and R-flurbiprofen, a purified enantiomer of the classical racemic non-steroidal anti-inflammatory drugs (NSAID), flurbiprofen, that retains the ability to specifically lower Aβ42. In the present study we evaluated the effects of scyllo-inositol and the combination treatment of scyllo-inositol+R-flurbiprofen on amyloid pathology and hippocampal-dependent memory function in 5XFAD mice, a model of Aβ pathology characterized by an enormous production of Aβ42. Our expectations were that the combination treatment of scyllo-inositol+R-flurbiprofen would have an additive effect in preventing Aβ accumulation and that cognition would be improved. Mice treated with scyllo-inositol exhibit 41 and 35% reduction in the deposition of the amyloid plaques stained by antibody against Aβ42 and Aβ40 respectively. Scyllo-inositol was not more effective when combined with R-flurbiprofen for the measures tested. Scyllo-inositol treated mice performed significantly better at the radial arm water maze (RAWM) task than untreated and scyllo-inositol+R-flurbiprofen treated mice.
authors.affiliation: Department of Veterans Affairs, VA Boston Healthcare System, Boston, MA 02130, USA.|Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA.
authors.forename: Nurgul
authors.initials: N
authors.lastname: Aytan
authors.affiliation: Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.|Department of Radiology, Harvard Medical School, USA.
authors.forename: Ji-Kyung
authors.initials: JK
authors.lastname: Choi
authors.affiliation: Department of Veterans Affairs, VA Boston Healthcare System, Boston, MA 02130, USA.|Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA.
authors.forename: Isabel
authors.initials: I
authors.lastname: Carreras
authors.affiliation: Department of Veterans Affairs, VA Boston Healthcare System, Boston, MA 02130, USA.|Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA.
authors.forename: Neil W
authors.initials: NW
authors.lastname: Kowall
authors.affiliation: Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.|Department of Radiology, Harvard Medical School, USA.
authors.forename: Bruce G
authors.initials: BG
authors.lastname: Jenkins
authors.affiliation: Department of Veterans Affairs, VA Boston Healthcare System, Boston, MA 02130, USA.|Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA.|Department of Radiology, Massachusetts General Hospital, Boston, MA 02114, USA.|Department of Radiology, Harvard Medical School, USA.
authors.forename: Alpaslan
authors.initials: A
authors.lastname: Dedeoglu
mesh_terms: D000544:Alzheimer Disease / Q000473:pathology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000187:drug effects* / Q000473:pathology; D003071:Cognition / Q000187:drug effects; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004797:Enzyme-Linked Immunosorbent Assay; D005480:Flurbiprofen / Q000008:administration & dosage*; D007294:Inositol / Q000008:administration & dosage*; D009682:Magnetic Resonance Spectroscopy; D008568:Memory / Q000187:drug effects; D051379:Mice; D008822:Mice, Transgenic; D018696:Neuroprotective Agents / Q000008:administration & dosage*
chemical_list: D018696:Neuroprotective Agents; C009217:scyllitol; D007294:Inositol; D005480:Flurbiprofen
keywords: Alzheimer's disease; Magnetic resonance spectroscopy; R-flurbiprofen; Scyllo-inositol